# Adalimumab Intralesional in Intestinal Strictures of Crohn's Disease Patients

> **NCT01986127** · PHASE3 · TERMINATED · sponsor: **Sara Varea** · enrollment: 26 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Adalimumab
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01986127
- **Lead sponsor:** Sara Varea
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-02-14
- **Primary completion:** 2018-06-30
- **Final completion:** 2018-06-30
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** slow recruitment
- **Last updated:** 2018-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01986127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01986127, "Adalimumab Intralesional in Intestinal Strictures of Crohn's Disease Patients". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT01986127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*